Fig. 2
Measurable residual disease (MRD) analysis in acute myeloid leukemia (AML) samples. a Serial MRD analysis of five FLT3 internal tandem duplication (FLT3-ITD) positive AML patients who remained in continuous clinical remission over the course of treatment (left) and five FLT3-ITD-positive AML patients who relapsed during follow-up (right). Each plot shows the results of a single patient: sequenced samples are marked and connected for better visibility; where applicable the relapse sample is marked in red. Marks on the x-axis represent samples which were analyzed but which were FLT3-ITD negative by our assay. When multiple ITD clones were detected at a certain time point, their variant allele frequencies (VAFs) were summed for plotting. b Serial MRD analysis of individual FLT3-ITD clones in the five FLT3-ITD positive AML patients who relapsed during follow-up. We analyzed the diagnosis and two to six follow-up samples, including the respective relapse sample, and plotted the change of each clone’s VAF over the sampled time points. Clones persisting from diagnosis (dx) to relapse (rl) are shown as blue circles, clones present at diagnosis but not relapse as red squares, clones present at relapse but not diagnosis as brown triangles; no clones were detected during remission only. Marks on the x-axis indicate that the respective clone was not detected in that sample. Patient IDs are provided below each plot; sample, ITD, and clinical patient details are presented in the supplementary tables 2–4. Abbreviations: after 2 cycles of chemotherapy (cy2), after end of treatment: 4th consolidation treatment (c4) or stem-cell transplantation (tx), follow-up months 1–12 (m1–12)
